KRAS and colorectal carcinoma: A study evaluating the correlation between KRAS/BRAF mutational status and clinicopathological features in advanced and recurrent CRC also found that in 60% patients with CRCs having BRAF mutations, the tumor metastasized to the peritoneum compared with approximately 15% patients with CRCs with other subtypes.